Corcept Therapeutics revenue and financials
$119.57Change from previous close: −2.02%Absolute change: −$2.46
In the fiscal year ended December 2025, Corcept Therapeutics reported revenue of $761.41M (+12.79% year over year). Net income was $99.65M, a net margin of 13.1%.
Fiscal year ending in December. Sources and method on the page Methodology and sources.
At a glance
- Revenue growth
- +12.79%
- 2025 vs 2024
- Net income growth
- −29.43%
- 2025 vs 2024
- Net margin
- 13.1%
- 2024: 20.9%
Financial data
Amounts in millions of USD; per-share values in USD; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 33.5 | -16.8 | 38.4 | 54.5 | 44.3 | 4.8 | 60.1 | 73.3 | 41.2 | 23.8 | 5.9 | 52.9 |
| Depreciation and amortization | 0.9 | 0.6 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.2 | 0.2 | 0.3 | 0.3 |
| Capital expenditure | -2.5 | -0.2 | -0.1 | — | -0.1 | -0.1 | -0.1 | -1.6 | -0.4 | — | — | -0.0 |
| Investing cash flow | -29.2 | 4.5 | -11.8 | 14.6 | 70.1 | -3.2 | -64.4 | -44.0 | -60.2 | -9.0 | 17.1 | -110 |
| Financing cash flow | -2.0 | 0.8 | -31.2 | -46.4 | -103 | -39.8 | -4.6 | -21.1 | -2.2 | -0.5 | 0.8 | -3.9 |
| Share repurchases | -11.5 | -5.8 | -36.5 | -50.6 | -115 | -43.3 | -7.0 | -23.4 | -5.4 | -2.2 | -1.0 | -5.1 |
| Effect of exchange rates | 0.0 | -0.3 | -0.0 | -0.3 | 1.4 | 0.4 | -0.8 | 0.5 | -0.0 | — | — | — |
| Net change in cash | 2.3 | -11.8 | -4.6 | 22.4 | 12.9 | -37.8 | -9.6 | 8.7 | -21.2 | 14.2 | 23.8 | -60.6 |
| Free cash flow | 31.0 | -17.0 | 38.4 | 54.5 | 44.2 | 4.7 | 59.9 | 71.7 | 40.8 | 23.8 | 5.9 | 52.9 |
| Levered free cash flow | 14.3 | 0.5 | 23.9 | 38.7 | 52.5 | -1.0 | 45.5 | 70.2 | 45.7 | 22.8 | 1.7 | 54.5 |